Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1069.18% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 88.04M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 88.04M.
Undervalued
The company’s latest PE is -12.75, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 147.01M shares, decreasing 9.22% quarter-over-quarter.
Held by Louis Moore Bacon
Star Investor Louis Moore Bacon holds 21.39K shares of this stock.